Meningococcal disease: Many severe amd life-threatening courses are preventable;Meningokokken-erkrankungen: Viele schwere und tödliche verläufe sind vermeidbar

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 49, 2004, Pages 2666-2671

  Dittmann, Sieghart ^a,b  

^a Deutschen Grunen Kreuzes eV   (Germany)

^b NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ANTIBIOTIC PROPHYLAXIS; CHEMOPROPHYLAXIS; DISEASE SEVERITY; HUMAN; INFECTION PREVENTION; INFECTION RATE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; REVIEW; SEROPREVALENCE;

EID: 10644284911     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-836094     Document Type: Review

References (14)

1. Abeyagunawardena AS, Goldblatt D et al. Risk of relapse after meningococcal conjugate vaccine in nephritic syndrome. Research letter. Lancet 2003; 362: 449-450
2. Campbell H, Ramsay M, Gungabissoon U et al. Impact of meningococcal C conjugate vaccination programme in England. Surveillance report from the Public Health Laboratory Service (PHLS) 7th quarterly report, July 31, 2002
3. Dittmann S. Meningokokken-Erkrankungen. 1. Auflage (Hrsg). Stuttgart: Thieme, 2003: 21-29
4. Fachinformation Mencevax® ACWY. GlaxoSmithKline Stand Juli 2001, 2001
5. Fachinformation Meningitec®. Meningokokken-Konjugatimpfstoff Serogruppe C. Wyeth Pharma. Stand der Information November 2001, 2001
6. Fachinformation Meningokokken-Impfstoff A+C Mérieux®. Aventis Pasteur MSD GmbH. Stand Juni 2000, 2000
7. Fachinformation Menjugate® Konjugat-Impfstoff gegen Meningokokken Serogruppe C Chiron Behring. Stand der Information Juni 2002, 2002
8. Fachinformation NeisVac-C™. Adsorbierter Meningokokken Serogruppe C-Polysaccharid-Konjugat-Impfstoff. Baxter Hyland Immuno Division. Stand der Information Mai 2001, 2001
9. Gesetz zur Verhütung und Bekämpfung von Infektionskrankheiten beim Menschen (Infektionsschutzgesetz -IfSG) vom 20. Juli 2000 (BGB11 S. 1045), 2000
10. Halperin S, McDonald J, Samson L et al. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study. Clin Invest Med 2002; 25: 243-251
11. Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut Stand: Juli 2004. Epidemiol Bull RKI 2004; 32: 235-250
12. Product Monograph Meninvact™. Meningococcal group C oligosaccharide conjugate vaccine (adsorbed). Aventis Pasteur MSD. Stand der Information 2002, 2002
13. Richmond P, Ed Kaczmarski E, Borrow R et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000; 181: 761-764
14. Richmond P, Borrow R, Goldblatt D et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001; 183: 160-163